by Team Attomarker | Feb 17, 2026 | Press Releases
Cheltenham and Exeter, United Kingdom, 17th February 2026 (Updated) EpitogenX and Attomarker Sign Strategic Co-Development Agreement to Advance Precision Immunology Diagnostics Across Multiple Diseases EpitogenX Ltd and Attomarker Ltd have announced the signing of a...
by Andrew Vincent | Feb 6, 2026 | Investment News, Press Releases
February 6, 2026 Attomarker launches Acceleration Round to further progress commercial, regulatory and business development milestones Attomarker has today commenced a funding acceleration round to support commercial rollout, regulatory progress, further clinical...